ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has warned medical practitioners, sellers and the public against use and sale of an antibiotic syrup 'Chemigel Suspension' as a batch of the said medicine has been found substandard, issuing a recall notice for the flawed product.
DRAP has disclosed that batch M319 of Chemigel Suspension, produced by Alkeme Pharma Laboratories located in Hyderabad, has been deemed substandard.
The sample in question was submitted to the laboratory by the Provincial Drug Inspector of Jamshoro. Upon testing at a drug analysis laboratory in Karachi, the batch of Chemigel Suspension was found to be substandard.
DRAP has issued a recall alert for Chemigel Suspension to the citizens, healthcare professionals, and pharmacists.
The syrup is commonly employed in the treatment of bacterial infections. Medical practitioners are urged to refrain from prescribing the affected batch.
The DRAP advisory says the utilisation of substandard medication can pose a grave risk to a patient's life and may lead to complications.
DRAP has asked the manufacturing company not to distribute the affected batch and to promptly withdraw it from the market.
Furthermore, chemists are requested to return any unopened, unaffected batches of Chemigel Suspension to the pharmaceutical company. Provincial DRAP teams will conduct surveillance in the medicine market to ensure compliance with this recall notice.
